Marshall Wace, LLP Lyra Therapeutics, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$4.12 - $7.51 $53,267 - $97,096	12,929 New	12,929 $74,000
Q4 2021 Feb 14, 2022	SELL	$4.22 - $9.41 $52,568 - $117,220	-12,457 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.06 - $9.43 $41,595 - $64,727	-6,864 Reduced 35.53%	12,457 $114,000
Q2 2021 Aug 13, 2021	SELL	$6.91 - $12.59 $190,764 - $347,572	-27,607 Reduced 58.83%	19,321 $155,000
Q1 2021 May 17, 2021	BUY	$10.38 - $15.61 $341,284 - $513,241	32,879 Added 234.03%	46,928 $544,000
Q4 2020 Feb 16, 2021	BUY	$9.28 - $13.88 $130,374 - $195,000	14,049 New	14,049 $160,000

32.2M

21.1K

400

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $5.73M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.